ElevateBio reels in $170M to push 6 cell, gene therapy programs – FierceBiotech

Barely a year after launching with $150 million to build cell and gene therapy companies, ElevateBio is at it again. This time, its picking up another $170 million to propel six programs into the clinic and get its centralized R&D and manufacturing hub up and running.

ElevateBio co-founders David Hallal, Mitchell Finer, Ph.D., and Vikas Sinha set up shop to tackle a bottleneck in cell and gene therapy: manufacturing. The holding company provides a centralized R&D and manufacturing site dubbed ElevateBio BaseCamp for its portfolio companies to bring cell and gene therapies from bench to bedside.

Since launch, ElevateBio has inked a 10-year deal with Massachusetts General Hospital to manufacture cell and gene therapies as well as to build cell and gene therapy biotechs. It has also unveiled two companies: AlloVir, which is developing a T-cell therapy that targets multiple viruses, and HighPassBio, which is working on a T-cell receptor treatment for leukemia.

RELATED: ElevateBio uncloaks with $150M to build cell and gene therapy biotechs

The new financing will bankroll the clinical development of six programs in 2020 and 2021, including treatments from AlloVir and HighPassBio as well as those being developed by companies ElevateBio has not yet made public.

[This] represents at least three additional new cell and gene therapies from not yet disclosed ElevateBio portfolio companies that include AAV-gene based technology as well as T-cell based therapeutics and we will launch these companies in the months to come, Hallal, ElevateBios CEO, told FierceBiotech via email.

It plans to start several phase 2 and phase 3 studies for AlloVirs Viralym-M program, which targets six viruses that commonly affect patients who receive stem cell transplants, and move a second program in diseases caused by community-acquired respiratory viruses into the clinic this year, Hallal added.

RELATED: ElevateBio founds HighPassBio to develop Fred Hutch cell therapy

The capital will also fund technology development and get ElevateBio BaseCamp fully operational.

We will continue to build our capabilities at ElevateBio BaseCamp that will increase our leadership position in the space as we have a unique integrated approach for cell and gene manufacturing, enabling technologies, and broad range of therapeutics all under one roof. At BaseCamp we expect to be performing cGMP manufacturing as early as next year, Hallal said.

All of ElevateBios backers returned for the series B round, including F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, and Samsara BioCapital. Newcomers The Invus Group, Surveyor Capital, EDBI and Vertex Ventures joined in.

AlloVir, which was founded on technology from the Center for Cell and Gene Therapy at Baylor College of Medicine, has also jumped into the hunt for treatments against the new coronavirus, SARS-CoV-2. It expanded its partnership with Baylor earlier this month to include work on off-the-shelf T-cell treatments that target the virus.

Here is the original post:
ElevateBio reels in $170M to push 6 cell, gene therapy programs - FierceBiotech

Stem Cells, Nerves Found to Interact in Cancer Progression – Pharmacy Times

Researchers at the Institute of Oral Biology of the University of Zurich have released 2 studies that examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

Their findings demonstrate that different stem cell populations are innervated in distinct ways and that innervation may be crucial for proper tissue regeneration, according to the study. They also demonstrate that cancer steam cells likewise establish contacts with nerves.

Stem cells can generate a variety of specific tissues that are increasingly being used for clinical application, such as the replacement of bone or cartilage, but are present in cancerous tissues and are involved in cancer progression and metastasis. Nerves are therefore fundamental for regulating the physiological and regenerative processes involving stem cells.

Using organ-on-a-chip technology, which relies on small 3-dimensional devices mimicking the basic function of human organs and tissues, the researchers demonstrated that both types of stem cells promoted neuronal growth. The dental pulp stem cells, however, yielded better results compared with bone marrow stem cells. They induced more elongated neurons, formed dense neuronal networks, and established close contacts with nerves.

Dental stem cells produce specific molecules that are fundamental for the growth and attraction of neurons. Therefore, stem cells are abundantly innervated, according to the study authors. The formation of such extended networks and the establishment of numerous contacts suggest that dental stem cells create functional connections with nerves of the face. Therefore, these cells could represent an attractive choice for the regeneration of functional, properly innervated facial tissue.

In the second study, the researchers examined the interaction between nerves and cancer stem cells found in ameloblastoma, an aggressive tumor of the mouth. They first demonstrated that ameloblastomas have stem cell properties and are innervated by facial neurons. When ameloblastoma cells were isolated and placed in the organ-on-a-chip devices, they retained not only their stem cell properties, but also attracted nerves and established contact with them.

Nerves appear to be fundamental for the survival and function of cancer stem cells. These results create new possibilities for cancer treatment using drugs that modify the communication between neurons and cancer stem cells. The researchers hope this opens unforeseen paths toward effective therapies against cancer.

The combination of advanced molecular and imaging tools and organ-on-a-chip technology offers an opportunity to reveal the hidden functions of neurons and their interactions with various stem cell types, in both healthy and pathological conditions.

Reference

Go here to read the rest:
Stem Cells, Nerves Found to Interact in Cancer Progression - Pharmacy Times

Canine Stem Cell Therapy Market by Players, Types and Applications with In-Depth Research On Industry Size … – The Financial News Daily

The Canine Stem Cell Therapy Market 2020 Research report provides information regarding Canine Stem Cell Therapy market share, size, trends, growth, cost structure, capacity, revenue and forecast 2026. This report also includes the overall and comprehensive study of the Canine Stem Cell Therapy Market with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Canine Stem Cell Therapy industry and provides data for making strategies to increase market growth and effectiveness.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Get a sample copy of the report at https://www.industryresearch.biz/enquiry/request-sample/15102654

The Canine Stem Cell Therapy market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Canine Stem Cell Therapy market research is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Canine Stem Cell Therapy Market Report is spread across 185 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Key players in global Canine Stem Cell Therapy market include:

Reasons to get this report:

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/15102654

Market segmentation, by Product Types:

Market segmentation, by Applications:

Market segmentation, by Regions:

Purchase this report (Price 3200 USD for a single-user license) https://www.industryresearch.biz/purchase/15102654

The report provides insights on the following pointers:

With tables and figures helping analyse worldwide Global Canine Stem Cell Therapy market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Some Points from TOC:

1 Industry Overview of Canine Stem Cell Therapy2 Major Manufacturers Analysis of Canine Stem Cell Therapy3 Global Price, Sales and Revenue Analysis of Canine Stem Cell Therapy by Regions 5 Europe Sales and Revenue Analysis of Canine Stem Cell Therapy by Countries6 Asia Pacific Sales and Revenue Analysis of Canine Stem Cell Therapy by Countries7 Latin America Sales and Revenue Analysis of Canine Stem Cell Therapy by Countries8 Middle East & Africa Sales and Revenue Analysis of Canine Stem Cell Therapy by Countries9 Global Market Forecast of Canine Stem Cell Therapy by Regions, Countries, Manufacturers, Types and Applications10 Industry Chain Analysis of Canine Stem Cell Therapy11 New Project Investment Feasibility Analysis of Canine Stem Cell Therapy12 Conclusion of the Global Canine Stem Cell Therapy Industry Market Professional Survey 2020

Continued

Detailed TOC of Global Canine Stem Cell Therapy Market @ https://www.industryresearch.biz/TOC/15102654

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Read this article:
Canine Stem Cell Therapy Market by Players, Types and Applications with In-Depth Research On Industry Size ... - The Financial News Daily

Blood donors in high demand – Dominion Post – The Dominion Post

As COVID-19 restricts residents from leaving their homes, Monongalia County is faced with a lack of blood donors.

The American Red Cross is facing a severe blood shortage due to an unprecedented number of blood drive cancellations during this coronavirus outbreak, said Jason Keeling, executive director of the American Red Cross local chapter.

Nationally, 7,000 Red Cross blood drives have been canceled with 63 being canceled in West Virginia.

Due to the cancellations, West Virginia is down 1,800 pints of blood from its typical intake, which would usually be enough to save up to 600 lives.

Keeling said contributions from the public are now desperately needed to save lives.

It inhibits the nations ability to have blood supply available for those that need it most such as cancer patients and those needing emergency procedures, Keeling said.

The Centers for Disease Control encourages anyone who is healthy even if they are social distancing to donate.

Keeling said additional precautionary measures are being taken to protect staff and those who choose to donate. He said everyone who comes in to donate is having their temperature taken first and using social distancing.

Those who have traveled abroad to China, Hong Kong, Macau, Iran, Italy and South Korea within the last 28 days are asked not to donate.

Hospitals, including WVU Medicine, have been working through the shortage to ensure those who need donations the most are not left without them.

Aaron Shmookler, assistant professor in the WVU department of pathology, anatomy, and laboratory medicine said WVU Medicine has postponed or canceled elective surgeries to avoid any complications.

Hematopoietic stem cell transplants, which is often used to treat cancer, have also been delayed. Schmookler said many of the blood products for this type of cellular therapy come from donors living outside the United States, which has made it difficult to administer the products to those who need them.

We have routine blood orders not being filled to 100%, Schmookler said. Although generally we have maintained stock of our inventory, over time a dwindling blood supply will make it more difficult to provide transfusion support when clinically indicated.

WVU Medicine has continued to treat patients with complex medical issues, including hemorrhagic shock, postpartum bleeding, surgery, cancer, and heart disease. Schmookler said blood has never been denied to those who need it.

In the case that the COVID-19 pandemic continues to escalate, and the blood supplies continue to diminish, Schmookler said it would force hospitals to make a difficult decision.

This coordinated effort is essential to ensure that the best clinical and laboratory decisions are made for each patient who needs blood, he said. The worst possible plan would be having to make very, very difficult and complex ethical decisions on who receives those last precious units of available blood. I am certainly hopeful for the best.

Several local blood drives are still scheduled for the coming weeks, and residents are encouraged to register by visiting http://www.redcrossblood.org.

Morgantown Red Cross drives will be held 9 a.m.-6 p.m. Monday and Tuesday, 11 a.m.-5 p.m. Wednesday, noon-5:30 p.m. Thursday and noon-5 p.m. Friday at the Morgantown Red Cross office.

From noon-4 p.m. April 7, an additional drive will be held at the Fresh Harvest Church in Morgantown.

I implore everyone who is healthy and eligible to please donate blood, Schmookler said. Call your local blood donation center, make an appointment, and help me and my professional clinical and laboratory colleagues in the hospital care for our relatives, our loved ones, and our friends.

By Gabriella Brown

TWEET @DominionPostWV

Excerpt from:
Blood donors in high demand - Dominion Post - The Dominion Post

Reversing The Ageing Process With Stem Cell Therapy – Version Weekly

It is a universally acknowledged fact that the majority of women refuse to age, the moment they reach the age of 40. The desire to turn back the clock is something that gets automatically etched on their minds, after hitting middle age. Making a wise choice from the wide range of anti-ageing solutions available for women can be a highly baffling affair, but understanding the skins needs is equally crucial.

So what exactly is ageing, that every person, especially women dread? It can be regarded as a complex process resulting in accrual changes in a persons body over. a period of time. Ageing occurs in fractions, because the stem cells which have the ability to renew themselves grow old as DNA gets damaged and changes occur in the overall physiology. As time passes by and people age, the majority of the cells present in their bodies get replaced and the ability of the body to produce more new cells gradually declines, Thus, anti-ageing retards the degeneration process of the body.

Post an anti-ageing fat stem cell treatment the skin shows prominent signs of turning softer while the body notices a remarkable surge of energy, resulting in improved sleeping and breathing patterns, controlled sugar levels, rebalanced hormones, increased metabolism, average weight loss and fading age spots. This all seems possible owing to the insertion of 30-50 million supercharged active stem cells.

Ageing is indeed complex, as its causes have not yet been completely understood. A big part of ageing occurs when the body is being attacked by inflammation and oxidative stress. Even though it is said that ageing is a natural process which is unavoidable, there is still scope to maintain health and stay young for both preventing age-related diseases and to enjoy the benefits of youth.

The desire to be younger is not exactly a new idea. The concept of anti-ageing has kept humankind occupied since ages, with the idea about staying healthy and fit with age and improving the quality of life. So with the rising evidence about the association of ageing diseases with adult stem cell exhaustion, it will not be surprising to witness an elevation of interest towards restoring the adult stem cell function to improve these conditions and to turn back the clock!

Read more here:
Reversing The Ageing Process With Stem Cell Therapy - Version Weekly

Positive Opinion from European Medicines Agency for Sanofi’s Isatuximab in R/R Multiple Myeloma – OncoZine

The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for isatuximab (Sarclisa; Sanofi), previously known as SAR650984.

The CHMP recommends isatuximab in combination with pomalidomide (Pomalyst; Celgene/Bristol-Myers Squibb) and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid; Celgene/Bristol-Myers Squibb)and a proteasome inhibitor such as bortezomib (Velcade; Takeda) and have demonstrated disease progression on the last therapy.

Following this positive review, the European Commission will review the CHMP recommendation and a final decision on the Marketing Authorisation Application for isatuximab in the European Union is expected in the coming months.

Isatuximab, developed in collaboration with ImmunoGen, was designated as an orphan medicine during its development.

A Significant BurdenAlthough considered a rare disease, multiple myeloma is the second most common hematologic malignancy, [1] with more than 138,000 new diagnoses worldwide every yearly.[2]

In Europe, approximately 39,000 patients are diagnosed with multiple myeloma each year.[3] Despite available treatments, multiple myeloma remains an incurable malignancy and is associated with a significant patient burden. Since multiple myeloma does not have a cure, most patients will relapse. The disease is generally associated with significant morbidity due to its end-organ destruction. As a result, the disease represents a major unmet medical need.

Multiple myeloma is a disease of the older population and its incidence in the African American population is twice that of the European American population. However, improvements in the treatment of the disease in the past couple of decades, beginning with the use of autologous stem cell transplantation followed by availability of novel treatments such as immunomodulatory drugs (ImIDs) and proteasome inhibitors (PIs) has transformed the natural history of the disease leading to longer survival times. [1]

ICARIA-MMThe CHMP positive opinion is based on data from ICARIA-MM study (NCT02990338), the first multicenter, multinational, randomized, open-label, two-arm, Phase III trial to evaluate an anti-CD38 monoclonal antibody (mAB) in combination with pom-dex.

The trial was conducted at 102 sites in Europe, North America, Asia, Australia, and New Zealand.

The study included 307 patients with relapsed and refractory multiple myeloma who had received at least two prior therapies including lenalidomide and a proteasome inhibitor. Patients were randomized (1:1) to receive either isatuximab-irfc with pomalidomide and low-dose dexamethasone (Isa-Pd,154 patients) or pomalidomide and low-dose dexamethasone (Pd, 153 patients).

In the ICARIA-MM study, isatuximab added to pom-dex (isatuximab combination therapy; n=154) demonstrated a statistically significant improvement of progression-free survival (PFS) with a median PFS of 11.53 months compared to 6.47 months with pom-dex alone (n=153; HR 0.596, 95% CI: 0.44-0.81, p=0.0010).

The combination therapy also demonstrated a significantly greater overall response rate (ORR) compared to pom-dex alone (60.4% vs. 35.3%, p<0.0001). In additional analyses, the isatuximab combination therapy compared to pom-dex alone showed a treatment benefit consistent across select subgroups reflective of real-world practice, including patients with high-risk cytogenetics, those aged 75 years and older, patients with renal insufficiency, and patients who were refractory to lenalidomide.

Adverse reactionThe most common adverse reactions (all grades occurring in 20% or more of patients) in patients who received isatuximab combination therapy were neutropenia (96%), infusion-related reactions (39%), pneumonia (31%), upper respiratory tract infection (57%) and diarrhea (26%). Serious adverse reactions that occurred in more than 5% of patients who received Sarclisa combination therapy included pneumonia (25.3%) and febrile neutropenia (12.3%). Permanent discontinuation of Sarclisa combination therapy due to an adverse reaction (Grades 3-4) occurred in 7% of patients, and 3% of patients discontinued due to an infusion-related reaction.

Relapsed and refractory multiple myeloma is a complicated disease that continuously develops resistance to treatment, creating a significant need for continued innovation, noted John Reed, M.D., Ph.D., Sanofis Global Head of Research & Development.

This positive CHMP opinion [..] brings us closer to our ambition to deliver a new treatment option for patients in Europe with relapsed and refractory multiple myeloma.

Mechanism of ActionCD38 is a transmembrane glycoprotein that highly and uniformly expressed on multiple myeloma cells and cell surface receptors, making it a potential target for antibody-based therapeutics such as isatuximab.

Isatuximab is an IgG1-derived monoclonal antibody (ATC code: L01XC38) that binds to a specific epitope on the CD38 receptor on multiple myeloma cells. It is designed to work through many mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. The clinical significance of these findings is under investigation.

Ongoing clinical studiesIsatuximab continues to be evaluated in multiple ongoing Phase III clinical trials in combination with current standard treatments across the multiple myeloma treatment continuum. It is also under investigation for the treatment of other hematologic malignancies and solid tumors.

FDA ApprovalEarlier this month, on March 2, 2020, isatuximab was approved by the U.S. Food and Drug Administration (FDA) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed and refractory multiple myeloma who had have received at least two prior therapies including lenalidomide and a proteasome inhibitor. In the United States, the generic name for isatuximab is isatuximab-irfc, with irfc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration.

In the United States, the launch price for isatuximab, which will be available in 100mg/5mL and 500mg/25mL single-dose vials for IV infusion, was has set at U.S. $ 650.00 per 100 mg vial and U.S. $ 3,250.00 per 500 mg vial. This represents a per infusion costs of U.S. $ 5,200.00 for an average patient treated in the United States. Based on the standard protocol, isatuximab is dosed every week for four weeks, and then every two weeks.

Sanofi did not disclose the pricing of the drug in Europe, which is based on reimbursement in each European member state.

According to analysts at the Jefferies Financial Group, isatuximab is expected to reach sales of more than U.S. $ 1 billion. However, the same anaylsts are concerned that the drug may struggle to catch up with daratumumab (Darzalex; Janssen Biotech), also an anti-CD38 drug, which was initially approved in 2015 and reached sales of nearly U.S. $ 3 billion in 2019.

Isatuximab is one of many multiple myeloma treatment options approved recently approved by reglators in the United States and Europe. With the potential approval novel therapies in the (near) future, including GSKs , investigational antibody-drug conjugate (ADC) belantamab mafodotin, also known as GSK2857916, a humanized, afucosylated, IgG1 anti-BCMA monoclonal antibody conjugated to monomethyl auristatin-F (MMAF), the number of novel drugs designed to treat multiple myeloma is growing exponentially.

Clinical trialsMultinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM) NCT02990338

References[1] Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676681. doi:10.1053/j.seminoncol.2016.11.004[2] International Myeloma Foundation. Myeloma Action Month. Online. Last accessed Match 26, 2020[3] Joo C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, da Silva MG. Long-term survival in multiple myeloma. Clin Case Rep. 2014;2(5):173179. doi:10.1002/ccr3.76

Read more:
Positive Opinion from European Medicines Agency for Sanofi's Isatuximab in R/R Multiple Myeloma - OncoZine

Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio – Business…

LONDON--(BUSINESS WIRE)--The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View original post here:
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Business...

HIV/AIDS cure: Second patient confirmed HIV-free and here’s the treatment that cured him – EconoTimes

HIV/AIDS was believed to have been first detected in humans in 1959 and in 1982 public health officials coined the term "Acquired Immunodeficiency Syndrome" or AIDS to describe the infection, but in 1983, the term was changed to HIV (Human Immunodeficiency Virus) after researchers discovered the virus that causes the disease, as per the AIDS Institute.

Just like with any newly-discovered virus strains that make people ill, for decades, there was no known cure for HIV/AIDS and lots of people already died from it. But after 50 years, it seems that a cure has finally been found and it is all thanks to the scientists, doctors and researchers who continuously work to find treatment for it and end the fight against this communicable disease.

But then, since this is just new doctors are not exactly declaring that they have found a cure already. Even if there are patients who already walked away from the hospitals HIV/AIDS-free, medical professionals just stated that they are getting really closer to finally having the cure.

The first cured patient

Timothy Brown was not named at first and was only referred to as the Berlin Patient and he the first to be identified as cured from the disease. He was diagnosed with HIV/AIDS in 1995 and was free from the virus after undergoing a stem cell procedure.

Being cured through this treatment was actually accidental because when Brown was diagnosed, he received the typical course of action for HIV-positive patients which is the antiretroviral treatment. However, later he was also diagnosed to have acute myeloid leukemia that required him to undergo a stem cell transplant.

While searching for a donor, his doctor came up with an idea and started to look for donors with a kind of genetic mutation that made them immune to the sexually transmitted disease. After finding a match and the stem cell procedure went ahead, his doctor was astonished to discover that not only his leukemia but his HIV/AIDS infection was also cured.

In 2007, Brown went into HIV remission and up to now, he doesnt show any signs of the infection. His treatment was published in The New England Journal of Medicine on Feb. 12, 2009.

The second patient

Since doctors succeeded in curing Timothy Brown, they tried the procedure on other patients but they failed to achieve the same results. But in 2019, Adam Castillejo who was known as the London Patient was cured using the same stem cell treatment

He was diagnosed in 2003 and in 2012, developed advanced Hodgkins lymphoma. As his body was rejecting chemotherapy, his doctors suggested stem cell transplant and found a donor match with the rare CCR5 mutation called CCR5-delta 32 and the procedure was done in 2016.

He was observed for 18 months before doctors confirmed he is cured. His treatment and results were published in the world's oldest, most prestigious and well-known medical journal, The Lancet. With the promising developments, it gave the world some hopes that infected people will be cured using the same treatment, but scientists still have to refine everything to officially declare it as an HIV/AIDS cure.

Follow this link:
HIV/AIDS cure: Second patient confirmed HIV-free and here's the treatment that cured him - EconoTimes

Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio…

LONDON--(BUSINESS WIRE)--The global hematopoietic stem cells transplantation (HSCT) market is poised to grow by USD 4.64 billion during 2020-2024, progressing at a CAGR of about 6% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Hematopoietic Stem Cells Transplantation (HSCT) Market Analysis Report by Type (Autologous HSCT and Allogeneic HSCT), Geographic segmentation (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/hematopoietic-stem-cells-transplantation-market-industry-analysis

The market is driven by the availability of technologically advanced equipment. In addition, the growing demand for personalized medicine is anticipated to boost the growth of the hematopoietic stem cells transplantation (HSCT) market.

The increasing efforts on improving the success rates of HSCT procedure is encouraging the adoption of advanced technologies and sophisticated instruments. For instance, Marrow Cellution, a patented technology, was developed by Ranfac. This technology is gaining traction in the market as it addresses the issues associated with conventional transplant syringe. It prevents contamination of peripheral blood during transplantation. In addition, this technology allows high-quality stem and progenitor cells to harvest within a narrow space. Thus, the availability of technologically advanced equipment is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Hematopoietic Stem Cells Transplantation (HSCT) Market Companies:

AllCells Corp.

AllCells Corp. provides mobilized leukopak, bone marrow and cord blood, whole blood, and leukopak. They also offer Cord Blood, which are collected from a single umbilical cord. They are cryopreserved and offered in the format of isolated cells. Cord Blood products include progenitor cells and CD34 HSCs.

bluebird bio Inc.

bluebird bio Inc. focuses on research, development, and commercialization of potentially transformative gene therapies. The company provides Zynteglo, which is a medicine used to treat patients of 12 years and older who are affected by a blood disorder known as beta thalassaemia.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates under various business segments, namely Imaging solutions, Healthcare and material solutions, and Document solutions. The company offers iCell Hematopoietic Progenitor Cells 2.0.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. focuses on research and development of therapeutic products for blood plasma volume expansion, orthopedics, oncology, diagnostic products for the early detection of cancer, neurological diseases and disorders, and more. The company provides OpRegen, which is in Phase I/IIa clinical trial.

Lonza Group Ltd.

Lonza Group Ltd. offers products through the following business segments: Pharma Biotech and Nutrition and Specialty ingredients. The company offers a wide range of stem cells such as bone marrow stromal cells, human peripheral blood CD14+ monocytes, cryopreseverd human CD34+ cells isolated from single donor, osteoclast precusor, and more.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Hematopoietic Stem Cells Transplantation (HSCT) Market Type Outlook (Revenue, USD Billion, 2020-2024)

Hematopoietic Stem Cells Transplantation (HSCT) Market Geographic Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Allogeneic Stem Cells Market Global Allogeneic Stem Cells Market by geography (Asia, Europe, North America, and ROW) and application (regenerative therapy and drug discovery and development).

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio...

Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors – The Union Journal

The electronic newsletter I Love My Freedom on a regular basis blasts out e-mails hawking ostentatious rip-offs as well as serpent oil, such as a dementia-reversing miracle therapy, a diabetes destroyer material as well as a life-saving cancer cells treatment that a Nazi drug store allegedly established at Hitlers command. Peppered in between these messages funded by third-party hucksters are main advertisements from Donald Trumps governmental reelection campaign.

For months, participants of the head of states internal circle consisting of Donald Trump Jr., Senate Majority Leader Mitch McConnell (R-Ky), previous House Speaker Newt Gingrich as well as also Trump himself have actually been releasing require contributions with the newsletter, which usually heads out 5 or even more times each day. Many receivers were most likely unintentionally subscribed; I Love My Freedom, the team that runs the eponymous newsletter, has actually obtained an expanding checklist of Americans call info with a concealed e-mail collecting system including an internet of pro-Trump Facebook web pages.

Right- wing political leaders, companies as well as media electrical outlets have a background of dealing with unethical entities behind the scenes to earn money as well as press their programs. The Trump campaigns service with I Love My Freedom is no exemption.

I Love My Freedom (e-mail information multiplied by HuffPost).

By layout, its e-mails seem theyre sent out straight from Trump as well as his allies, though theyre in fact dispersed by means of [emailprotected] At all-time low, they birth please notes noting they were spent for by either the National Republican Senatorial Committee, its House equivalent, the McConnell Senate Committee, or the Trump Make America Great Again Committee (which is collectively run by the Republican National Committee as well as Trumps reelection campaign).

Renting out accessibility to collected e-mail listings is a typical as well as very profitable method worked out by traditional as well as liberal teams alike, commonly for political fundraising objectives. But points obtain morally dirty when e-mail representatives do not veterinarian their enrollers which can lead to e-mail receivers being flooded with ripoffs as well as scams, like the counterfeit cancer cells treatment. In this instance, nonetheless, the genuine inquiry is whether Trumps group troubled to veterinarian I Love My Freedom.

The campaign did not react to HuffPosts ask for remark.

I Love My Freedom, which makes up the newsletter as well as a conservative blog site called Trending Politics, belongs to Making Web LLC, a rare advertising company thats signed up in Minnesota to a 51- year-old male called Allan G. Ferretti.

Through the newsletter alone, I Love My Freedom has actually enhanced a list of aggressive rip-offs consisting of some that misleadingly link Trump, in spite of its negotiations with his campaign. Hours prior to dispersing a fundraising e-mail from the McConnell Senate Committee this month, I Love My Freedom discharged off a funded message advertising a breakthrough stem cell therapy which it baselessly suggested Trump is getting.

This has got Liberals jumping out of their seats, the e-mail checks out. President Trump is in perfect health how is it that hes so seemingly immune to old age? Well in recent years, billionaires like President Trump have increasingly turned to the power of Stem Cells.

Titled Trump Health Bombshell, the e-mail web links to a rambling item pitch that promotes $67 containers of stem cell tablets as the Holy Grail of aging backwards. These tablets make cells inside your body become physically younger, it asserts, without supplying a shred of clinical proof. I Love My Freedom has likewise spammed its customers with enrollers get-rich-quick plans consisting of a secret IRS loophole, as well as has actually routed them to video clips recommending elders ought to exchange their recommended medicines for tricksters supplements also advising that they can pass away if they do not.

Recent newsletter versions have actually circulated actual phony information, as well, installing advertisements camouflaged as write-ups that connect to internet sites stealthily copying genuine media electrical outlets.

I Love My Freedom e-newsletters have actually included misleading advertisements resulting in phony information websites copying genuine electrical outlets..

One such advertisement includes the message Royal Family Mourns As Tragedy Is Confirmed, along with a picture of Meghan Markle, the Duchess ofSussex Clicking on it causes a web site imitating U.S.A. Today that goes crazy regarding a skin care line, which it incorrectly asserts Markle released. Another, birthing the heading [BREAKING NEWS] Prayers Go Out to Oprah Winfrey, web links to a fraudulent information website marketing a Brain Booster supplement, which it brazenly states is in charge of Winfreys occupation success.

In enhancement to Trump, his oldest kid, McConnell as well as Gingrich, I Love My Freedom has actually likewise sent fundraising e-mails in behalf of previous White House press assistant Sarah Huckabee Sanders, House Minority Leader Kevin McCarthy (R-Calif), House Republican Whip Steve Scalise (R-La), previous United Nations Ambassador Nikki Haley,Rep Elise Stefanik (R-N.Y.),Rep David Joyce (R-Ohio), previous White House Deputy Chief of Staff Karl Rove as well as National Republican Congressional Committee Chairman TomEmmer

All were spent for by the NRCC, NRSC, McConnell Senate Committee or the Trump Make America Great AgainCommittee Only the NRCC reacted to an ask for remark.

We rented this list to prospect new donors. We do our best to vet each vendor, but similar to renting a car, it is impossible to know or control what every other renter does with a list they too are renting, spokesperson Chris Pack informed HuffPost.

We will not be using this vendor going forward.

I Love My Freedom constructed its cash-cow e-mail realm by spending virtually $2 million right into Facebook advertisements, which attract individuals in with clickbait surveys or pledges of free MAGA equipment, as well as result in web pages advising them to send their e-mail addresses. This immediately indications them as much as obtain the newsletter, in addition to its numerous funded messages.

The team likewise earns money by marketing Trump- themed product such as Make Liberals Cry Again hats, as well as organizing third-party advertisements on Trending Politics which was seen a million times last month alone, according to electronic analytics device ComparableWeb

I Love My Freedom did not accept HuffPosts ask for a meeting.

I Love My Freedom makes use of clickbait Facebook advertisements to gather individualss e-mails, after that subscribes them to its newsletter.

Ferretti released ilovemyfreedom.org in addition to the Facebook web page Trump for President Fan Club (currently President Donald Trump Fan Club, which has 1.6 million fans) in the summertime of 2015, as reporter April Glaser reported last loss in a write-up regarding I Love My Freedoms viral development on Facebook.

Its among greater than a lots preferred web pages the team runs to run its countless Facebook advertisements, consisting of Donald Trump Is My President, Donald Trump 2020 Voters, President Trump Has My Vote, Donald Trumps Americans, Team Trump Fan Club, The President Trump Fan Club, We Need Trump 2020 as well as President Trumps Patriot Army.

These web pages create a stream of hyper-partisan memes as well as Trending Politics post to their target market of millions. Boosted by Facebooks formula, the advertisements which largely target elders are in some cases seen thousands of countless times each.

This looks like an operation thats got a very highly engaged audience that would be a prime target for a lot of conservative politicians to try to raise grassroots money from, stated Michael Beckel, research study supervisor at the political reform team Issue One.

When you run a pro-Trump Facebook team with greater than a million participants, that can make your [email] checklist an appealing possession.

Trumps campaign has actually currently gathered a citizen e-mail checklist thats so big it leases it out to outdoors celebrations. So why would certainly his group wish to fundraise with I Love My Freedoms checklist particularly provided the teams historical connections to grifters as well as scam artist?

Its type of striking that the Trump campaign is making a financial investment in [I Love My Freedoms] checklist, kept in mindBeckel But a t completion of the day, he stated, much more e-mails still means more potential voters or donors for them.

Calling all HuffPost superfans!

Sign up for subscription to come to be a starting participant as well as aid form HuffPosts following phase

Visit link:
Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors - The Union Journal